These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 25266991)
1. The role of nitisinone in tyrosine pathway disorders. Lock E; Ranganath LR; Timmis O Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991 [TBL] [Abstract][Full Text] [Related]
2. From Weed Killer to Wonder Drug. Lock EA Adv Exp Med Biol; 2017; 959():175-185. PubMed ID: 28755195 [TBL] [Abstract][Full Text] [Related]
3. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Santra S; Baumann U Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479 [TBL] [Abstract][Full Text] [Related]
4. NTBC and alkaptonuria. Anikster Y; Nyhan WL; Gahl WA Am J Hum Genet; 1998 Sep; 63(3):920-1. PubMed ID: 9718357 [No Abstract] [Full Text] [Related]
5. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia. Med Lett Drugs Ther; 2016 Oct; 58(1505):e132. PubMed ID: 27701365 [No Abstract] [Full Text] [Related]
6. Predicting tyrosinaemia: a mathematical model of 4-hydroxyphenylpyruvate dioxygenase inhibition by nitisinone in rats. Ward JP; Dunster JL; Derks G; Mistry P; Salazar JD Math Med Biol; 2017 Sep; 34(3):335-390. PubMed ID: 27305933 [TBL] [Abstract][Full Text] [Related]
7. A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria. Suzuki Y; Oda K; Yoshikawa Y; Maeda Y; Suzuki T J Hum Genet; 1999; 44(2):79-84. PubMed ID: 10083729 [TBL] [Abstract][Full Text] [Related]
8. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I. Kassel R; Sprietsma L; Rudnick DA J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819 [No Abstract] [Full Text] [Related]
9. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone. Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione. Ellis MK; Whitfield AC; Gowans LA; Auton TR; Provan WM; Lock EA; Smith LL Toxicol Appl Pharmacol; 1995 Jul; 133(1):12-9. PubMed ID: 7597701 [TBL] [Abstract][Full Text] [Related]
11. [New drugs; nitisinone]. Cohen AF; van Bronswijk H Ned Tijdschr Geneeskd; 2006 Nov; 150(46):2541-2. PubMed ID: 17152330 [TBL] [Abstract][Full Text] [Related]
12. Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism. Hanauske-Abel HM; Popowicz A; Remotti H; Newfield RS; Levy J J Pediatr Gastroenterol Nutr; 2002 Jul; 35(1):73-8. PubMed ID: 12142814 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria. Laschi M; Bernardini G; Dreassi E; Millucci L; Geminiani M; Braconi D; Marzocchi B; Botta M; Manetti F; Santucci A ChemMedChem; 2016 Apr; 11(7):674-8. PubMed ID: 26947423 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione. Mitchell GA Hum Exp Toxicol; 1996 Feb; 15(2):179-81. PubMed ID: 8645506 [No Abstract] [Full Text] [Related]
15. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. Lock EA; Ellis MK; Gaskin P; Robinson M; Auton TR; Provan WM; Smith LL; Prisbylla MP; Mutter LC; Lee DL J Inherit Metab Dis; 1998 Aug; 21(5):498-506. PubMed ID: 9728330 [TBL] [Abstract][Full Text] [Related]
16. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool. Milan AM; Hughes AT; Davison AS; Devine J; Usher J; Curtis S; Khedr M; Gallagher JA; Ranganath LR Ann Clin Biochem; 2017 May; 54(3):323-330. PubMed ID: 28081634 [TBL] [Abstract][Full Text] [Related]
17. Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria. Mistry JB; Jackson DJ; Bukhari M; Taylor AM Clin Rheumatol; 2016 Feb; 35(2):513-6. PubMed ID: 26024586 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Hall MG; Wilks MF; Provan WM; Eksborg S; Lumholtz B Br J Clin Pharmacol; 2001 Aug; 52(2):169-77. PubMed ID: 11488774 [TBL] [Abstract][Full Text] [Related]
19. Perturbations of tyrosine metabolism promote the indolepyruvate pathway via tryptophan in host and microbiome. Gertsman I; Gangoiti JA; Nyhan WL; Barshop BA Mol Genet Metab; 2015 Mar; 114(3):431-7. PubMed ID: 25680927 [TBL] [Abstract][Full Text] [Related]
20. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). Holme E; Lindstedt S J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]